Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Plasma levels of COL10A1 show promise as a biomarker for pancreatic ductal adenocarcinoma (PDAC). This study indicates COL10A1 is a potential diagnostic and prognostic tool for PDAC, useful in liquid biopsies.
Area Of Science
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background
- Collagen type 10 alpha 1 (COL10A1) is upregulated in pancreatic cancer and promotes tumor development.
- Plasma COL10A1 levels have shown diagnostic utility in other cancers, but its role in pancreatic cancer remains unclear.
Purpose Of The Study
- To investigate the diagnostic and prognostic value of plasma COL10A1 levels in pancreatic ductal adenocarcinoma (PDAC).
Main Methods
- Analysis of COL10A1 expression in PDAC tissues using TCGA and GEO datasets.
- Measurement of plasma COL10A1 levels in PDAC patients and healthy volunteers.
- Correlation analysis between COL10A1 levels and clinical characteristics.
- Evaluation of diagnostic and prognostic efficacy of plasma COL10A1.
Main Results
- COL10A1 expression was significantly higher in PDAC tissues than normal tissues and correlated with advanced tumor stages.
- High COL10A1 expression was associated with worse recurrence-free and overall survival.
- Plasma COL10A1 demonstrated high diagnostic accuracy for PDAC (AUC=0.926), with 81% sensitivity and 100% specificity.
- Time-dependent AUCs at 1 and 3 years were 0.71 and 0.74, respectively.
Conclusions
- Plasma COL10A1 levels possess significant diagnostic and prognostic value in PDAC.
- COL10A1 is a potential biomarker for PDAC, applicable in liquid biopsy strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.